Is lapatinib included in medical insurance?

Lapatinib (Lapatinib) is an oral small molecule targeted drug commonly used to treat breast cancer. It belongs to a class of drugs called tyrosine kinase inhibitors (tyrosine kinase inhibitors), which slow down the progression of the disease by interfering with the signaling pathways within tumor cells and preventing the growth and division of cancer cells.

Lapatinib is already on the market in China, but it has not yet been included in medical insurance. Patients can buy it domestically at a price of about 5,000 to 6,000 yuan. For specific prices, please consult the local hospital pharmacy. There are original lapatinib drugs and generic drugs abroad. The original drug is cheaper than the original drug in Türkiye, which costs more than 2,000 yuan. Generic drugs include Indian generic drugs and Bangladeshi generic drugs, and the price is around a few hundred yuan. The ingredients of domestic original drugs, foreign original drugs and generic drugs are basically the same.

Lapatinib is primarily used to treat HER2-positive breast cancer, a specific type of breast cancer that accounts for about 20% of all breast cancer cases. HER2 (human epidermal growth factor receptor 2) is a protein that is overexpressed on certain cancer cells, causing these cells to grow and spread excessively. Lapatinib's mechanism of action involves inhibiting the activity of HER2 and EGFR (epidermal growth factor receptor), thereby reducing cancer cell proliferation and survival.

Unlike many chemotherapy drugs, lapatinib is a targeted drug, so its therapeutic effect is more specific and helps reduce damage to normal cells, thereby reducing the risk of adverse reactions. However, patients may still experience some discomfort during treatment with lapatinib, such as diarrhea, rash, fatigue, and nausea. Therefore, patients need to be monitored and managed under the guidance of a physician when using lapatinib.

Lapatinib is often given with other drugs, such as trastuzumab , to increase efficacy. This combination therapy helps increase patient response to HER2-positive breast cancer, thereby improving survival and quality of life.